Insmed (INSM) PT Slashed to $53 at Cantor Fitzgerald, Lower Sales Forecast for Arikayce and Increased OpEx Weigh In
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim lowered the price target on Insmed (NASDAQ: INSM) to $53.00 (from $60.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
